BIO INX
Develops and commercializes high-performance bio-inks and materials for 3D bioprinting and biofabrication applications.
- CEO / Founder
- Jasper Van Hoorick
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- €700K
- Latest Round
- Seed
- Key Investors
- Ghent University, Vrije Universiteit Brussel, Start it @KBC, Innovation Network for Advanced Materials (INAM), VLAIO
Technology & Products
Key Products
Bio-inks; Biomaterials
Technological Advantage
Proprietary bio-ink formulations designed for high-resolution bioprinting and biocompatibility, supported by a multidisciplinary team with deep academic roots.
Differentiation
Value Proposition
Leverages 20 years of academic expertise in polymer chemistry to provide optimized bio-inks that bridge the gap between research and commercial biofabrication.
How They Differentiate
Differentiates through a strong academic foundation in polymer science and a focus on interdisciplinary biomaterials for specific tissue engineering needs.
Market & Competition
Target Customers
Research institutions, biotech firms, and medical researchers focused on tissue engineering and biofabrication.
Industry Verticals
Biomedical; Tissue Engineering; Biofabrication
Competitors
CELLINK (BICO), CollPlant Biotechnologies, Advanced BioMatrix
Growth & Milestones
Growth Metrics
Combined 20 years of team expertise in polymers and biomaterials.
Major Milestones
Spin-off from Ghent University and Vrije Universiteit Brussel in 2018; Appointment of Dr. Liesbeth Ceelen and Prof. Khoon Lim to the Advisory Board
Notable Customers
SCK CEN (AstroCardia project), Carl ROTH, Yamato Scientific, Nanoscribe, Readily3D